The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults

Tutunchi, Helda; Saghafi-Asl, Maryam; Asghari‐Jafarabadi, Mohammad; Ostadrahimi, Alireza

doi:10.1186/s13104-020-05059-5

Cited by 22 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prevalence of non‐alcoholic fatty liver disease (NAFLD) is increasing worldwide 1 . The disease can range in spectrum from simple steatosis to non‐alcoholic steatohepatitis (NASH), characterised by hepatic fat accumulation with inflammation, which can progress to fibrosis, cirrhosis and finally hepatocellular carcinoma 2,3 . According to a recent meta‐analysis, the global prevalence of NAFLD is reported to be 25.24%, with greatest prevalence in the Middle East and South America and lowest in Africa 4 .…”

Section: Introductionmentioning

confidence: 99%

The association of the steatosis severity, NAFLD fibrosis score and FIB‐4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross‐sectional study

Tutunchi

Naeini

Ebrahimi-Mameghani

et al. 2021

Int J Clinical Practice

Self Cite

View full text Add to dashboard Cite

Objectives Obesity and dyslipidaemia are the major risk factors for non‐alcoholic fatty liver disease (NAFLD), and are known to increase cardiovascular disease (CVD), which is the leading cause of death in NAFLD patients. The present cross‐sectional study aimed to investigate associations among severity of hepatic steatosis, NAFLD fibrosis score and atherogenic lipid profile. Methods A total of 265 patients with NAFLD confirmed by ultrasonographic findings were included. The NAFLD fibrosis score and the fibrosis‐4 (FIB‐4) index were used to classify the probability of fibrosis as low, intermediate and high probability. Serum lipids including total cholesterol (TC), triglyceride (TG), low‐density lipoprotein cholesterol (LDL‐C) and high‐density lipoprotein cholesterol (HDL‐C) were measured, and then TC/HDL‐C, LDL‐C/HDL‐C, TG/HDL‐C and non HDL‐C/HDL‐C ratios were determined. Fasting blood sugar (FBS), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were also assessed. The homeostatic model assessment for insulin resistance (HOMA‐IR) was calculated. Results The severity of hepatic steatosis was positively correlated with TC/HDL‐C (r = 0.29, P = .002), LDL‐C/HDL‐C (r = 0.32, P < .001), TG/HDL‐C (r = 0.36, P < .001) and non‐HDL‐C/HDL‐C (r = 0.24, P = .001) ratios. Similarly, these parameters were positively correlated with NAFLD fibrosis score and FIB‐4 index (P < .05). In addition, alanine aminotransferase and aspartate aminotransferase levels were positively correlated with TG/HDL‐C ratio (r = 0.31, P = .003; and r = 0.27, P = .001 respectively). With increasing the severity of hepatic steatosis and NAFLD fibrosis score, the mean of all lipid ratios increased significantly (P < .01 and P < .05, respectively). Importantly, after controlling for potential confounders including age, gender, physical activity level, body mass index, waist circumference and HOMA‐IR, the severity of steatosis, NAFLD fibrosis score and FIB‐4 index remained independent predictors of atherogenic lipid profile. Conclusions Severity of hepatic steatosis, NAFLD fibrosis score and FIB‐4 index were significantly correlated with atherogenic lipid profile. As NAFLD is high among patients with metabolic risk factors for CVD, their dyslipidaemia should be aggressively managed.

show abstract

Section: Introductionmentioning

confidence: 99%

The association of the steatosis severity, NAFLD fibrosis score and FIB‐4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross‐sectional study

Tutunchi

Naeini

Ebrahimi-Mameghani

et al. 2021

Int J Clinical Practice

Self Cite

View full text Add to dashboard Cite

show abstract

“…2,5,6 NAFLD is characterized by an atherogenic lipid profile including increased TG, lowdensity lipoprotein cholesterol (LDL-C), and very lowdensity lipoprotein cholesterol (VLDL-C) concentrations and a reduced high-density lipoprotein cholesterol (HDL-C) level leading to a significantly increased risk TUOMS P R E S S of cardiovascular disease (CVD). [7][8][9] It has also been suggested that total cholesterol (TC)/HDL-C, LDL-C/ HDL-C, and TG/HDL-C ratios are better mirror of the metabolic and clinical interactions between lipid fractions and have higher predictive values than isolated parameters used independently in disease states. 10 Furthermore, non-HDL-C which reflects all of the major lipoproteins associated with a higher risk of CVD may better identify abnormal lipid profile in patients with NAFLD.…”

Section: Introductionmentioning

confidence: 99%

Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial

Tutunchi

Naeini

Saghafi-Asl

et al. 2020

Health Promot Perspect

Self Cite

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in the world. The current interventional trial aimed to evaluate the effects of supplementation with oleoylethanolamide (OEA) in combination with weight loss intervention on some atherogenic indices as well as hematological parameters in patients newly diagnosed with NAFLD. Methods: In this triple-blinded, randomized, placebo-controlled clinical trial, 76 obese patients with NAFLD confirmed by ultra-sonographic findings were randomly assigned to receive a weight reduction diet plus either 250 mg OEA (n=38) or placebo (n=38) for 12 weeks. Atherogenic factors including total cholesterol/high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol (LDL-C)/HDL-C, triglyceride (TG)/HDL-C, non-HDL-C/HDL-C ratios and non-HDL-C level, as well as hematological parameters were assessed before and after intervention. Results: After adjustment for potential confounding factors, between group analyses demonstrated a significantly lower LDL-C/HDL-C, TG/HDL-C, and non-HDL-C/HDL-C ratios in the OEA group compared to the placebo, post-intervention (95% confidence interval [CI]:0.06 to 0.85, P = 0.024; 95% CI: -2.06 to -0.05, P = 0.039; 95% CI: -1.05 to -0.02, P = 0.042,respectively). Additionally, OEA supplementation could significantly decrease the levels of red blood cell distribution width (RDW) compared to the placebo at the endpoint after considering potential confounding variables (95% CI: -0.56 to -0.003, P = 0.041). No significant differences were found between the two study groups in terms of other hematological parameters. Conclusion: The results of the current study indicated that OEA supplementation had beneficial effects on LDL-C/HDL-C, TG/HDL-C, and non-HDL-C/HDL-C ratios as well as RDW in obese patients with NAFLD. Trial Registration: IRCT20110530006652N2; https://www.irct.ir/trial/37228.

show abstract

“…NAFLD is associated with a highly atherogenic lipoprotein profile, characterized by high serum TG, low-density lipoprotein (LDL-C), and apolipoprotein B (ApoB) concentrations and a low HDL-C concentration [ 7 , 8 ]. In addition, previous studies have shown that hypertriglyceridemia is one of the risk factors for NAFLD [ 9 ], and that the prevalence and degree of hypertriglyceridemia significantly correlate with the severity of NAFLD [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test

et al. 2021

View full text Add to dashboard Cite

Background Nonalcoholic fatty liver disease (NAFLD) has become one of the most common chronic liver diseases worldwide. Triglyceride (TG) accumulation is central to NAFLD development. People now spend most of their day in the postprandial state, and the measurement of postprandial blood lipid concentration can make up for the lack of simple detection of fasting blood lipids. Postprandial triglyceride (PTG) is commonly used as a surrogate for postprandial blood lipid concentrations, and many studies have shown that PTG is a risk factor for NAFLD. The aim of the present study was to investigate the relationship between PTG concentration during oral fat tolerance testing (OFTT) and NAFLD. Methods A total of 472 Chinese adults, aged 25 to 65 years, were enrolled in the study. All the participants underwent OFTT. The serum concentrations of TG and other lipids were measured, and their relationships with NAFLD were analyzed. Results Of the 472 participants, 155 were diagnosed with NAFLD. The fasting and postprandial TG concentrations of the participants with NAFLD were higher than those of healthy participants (P < 0.05). The TG concentrations of the healthy participants peaked 4 h postprandially, whereas those of the participants with NAFLD peaked 6 h postprandially and reached higher peak values. Postprandial TG concentration was significantly associated with a higher risk of NAFLD. Conclusions High PTG is positively related to a higher risk of NAFLD, and the PTG concentrations of patients with NAFLD are higher than in healthy individuals, with a delayed peak. Therefore, 4-h PTG may represent a potential marker of NAFLD. Trial registration ChiCTR1800019514.

show abstract

The relationship between severity of liver steatosis and metabolic parameters in a sample of Iranian adults

Cited by 22 publications

References 24 publications

The association of the steatosis severity, NAFLD fibrosis score and FIB‐4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross‐sectional study

The association of the steatosis severity, NAFLD fibrosis score and FIB‐4 index with atherogenic dyslipidaemia in adult patients with NAFLD: A cross‐sectional study

Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial

A correlation study of the relationships between nonalcoholic fatty liver disease and serum triglyceride concentration after an oral fat tolerance test

Contact Info

Product

Resources

About